Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037004 | 0.88 | SLC6A9 (0.47) | SLC6A9ALDH1A1LMNASMN1; SMN2FAAH | |
| SCHEMBL6859119 | 0.87 | SMN1; SMN2 (0.53) | SLC6A9ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL14701530 | 0.84 | LMNA (0.57) | SLC6A9ALDH1A1LMNASMN1; SMN2FAAH | |
| SCHEMBL18170175 | 0.84 | SLC6A9 (0.56) | SLC6A9ALDH1A1LMNASMN1; SMN2FAAH | |
| SCHEMBL14535420 | 0.82 | ALDH1A1 (0.59) | SLC6A9ALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL14701528 | 0.82 | ALDH1A1 (0.59) | SLC6A9ALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL19658757 | 0.81 | HTT (0.71) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL14535437 | 0.81 | HTT (0.71) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL14701536 | 0.79 | SLC6A9 (0.49) | SLC6A9ALDH1A1LMNASMN1; SMN2FAAH | |
| SCHEMBL14701537 | 0.79 | SLC6A9 (0.49) | SLC6A9ALDH1A1LMNASMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809338-B2 | 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130040964-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040964-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | ICAM1, ITGB3, VCAM1 | SLC6A9 4174/4885ALDH1A1 368/4885LMNA 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.